Toshihiro Toyoshima

Spring Asset Management Ltd. (Hong Kong) engages in the management of assets of Spring Real Estate Investment Trust (REIT). The company was founded on January 29, 2013 and is headquartered in Hong Kong.

Spring Asset Management Ltd. (Hong Kong) engages in the management of assets of Spring Real Estate Investment Trust (REIT). The company was founded on January 29, 2013 and is headquartered in Hong Kong.

Mercuria Investment Co. Ltd. (Mercuria Investment) is an independent venture capital firm headquartered in Tokyo, Japan. The firm was founded in 2005 as a joint venture of Development Bank of Japan Inc. and Asuka Asset Management Co. Ltd.

Development Bank of Japan, Inc. (DBJ) is a financial institution created in 1999 through the regrouping of JDB-Japan Development Bank and Hokkaido-Tohoku Development Finance Public Corp., and the adjunction of the finance divisions of Japan Regional Development Corp. and Japan Environment Corp. The firm is headquartered in Tokyo, Japan with a network of domestic branches, as well as overseas offices in New York and London, and a subsidiary in Singapore. Formerly government-owned, DBJ underwent restructuring in 2007. The current structure was established in 2008 when a several-year privatization process was initiated. DBJ is a socially-committed investor. It provides long-term complementary financing and debt guarantees to promote the development of regional economies in Japan. The firm also supports technology-based enterprises, urban redevelopment and socially-desirable projects. It operates in collaboration with private sector financial institutions and favor projects with high policy content. As part of their investment activities, DBJ manages private equity funds.

Spring Asset Management Ltd. (Hong Kong) engages in the management of assets of Spring Real Estate Investment Trust (REIT). The company was founded on January 29, 2013 and is headquartered in Hong Kong.

Mercuria Investment Co., Ltd. provides investment advisory and management. Its activities include corporate investment, real estate, lease, and infrastructure. The company was founded on October 5, 2005 and is headquartered in Tokyo, Japan.

Mercuria Investment Co., Ltd. provides investment advisory and management. Its activities include corporate investment, real estate, lease, and infrastructure. The company was founded on October 5, 2005 and is headquartered in Tokyo, Japan.

Mercuria Investment Co. Ltd. (Mercuria Investment) is an independent venture capital firm headquartered in Tokyo, Japan. The firm was founded in 2005 as a joint venture of Development Bank of Japan Inc. and Asuka Asset Management Co. Ltd.

Mercuria Investment Co., Ltd. provides investment advisory and management. Its activities include corporate investment, real estate, lease, and infrastructure. The company was founded on October 5, 2005 and is headquartered in Tokyo, Japan.

Mercuria Investment Co., Ltd. provides investment advisory and management. Its activities include corporate investment, real estate, lease, and infrastructure. The company was founded on October 5, 2005 and is headquartered in Tokyo, Japan.

Mercuria Investment Co. Ltd. (Mercuria Investment) is an independent venture capital firm headquartered in Tokyo, Japan. The firm was founded in 2005 as a joint venture of Development Bank of Japan Inc. and Asuka Asset Management Co. Ltd.

Development Bank of Japan, Inc. (DBJ) is a financial institution created in 1999 through the regrouping of JDB-Japan Development Bank and Hokkaido-Tohoku Development Finance Public Corp., and the adjunction of the finance divisions of Japan Regional Development Corp. and Japan Environment Corp. The firm is headquartered in Tokyo, Japan with a network of domestic branches, as well as overseas offices in New York and London, and a subsidiary in Singapore. Formerly government-owned, DBJ underwent restructuring in 2007. The current structure was established in 2008 when a several-year privatization process was initiated. DBJ is a socially-committed investor. It provides long-term complementary financing and debt guarantees to promote the development of regional economies in Japan. The firm also supports technology-based enterprises, urban redevelopment and socially-desirable projects. It operates in collaboration with private sector financial institutions and favor projects with high policy content. As part of their investment activities, DBJ manages private equity funds.

Development Bank of Japan, Inc. (DBJ) is a financial institution created in 1999 through the regrouping of JDB-Japan Development Bank and Hokkaido-Tohoku Development Finance Public Corp., and the adjunction of the finance divisions of Japan Regional Development Corp. and Japan Environment Corp. The firm is headquartered in Tokyo, Japan with a network of domestic branches, as well as overseas offices in New York and London, and a subsidiary in Singapore. Formerly government-owned, DBJ underwent restructuring in 2007. The current structure was established in 2008 when a several-year privatization process was initiated. DBJ is a socially-committed investor. It provides long-term complementary financing and debt guarantees to promote the development of regional economies in Japan. The firm also supports technology-based enterprises, urban redevelopment and socially-desirable projects. It operates in collaboration with private sector financial institutions and favor projects with high policy content. As part of their investment activities, DBJ manages private equity funds.

Mercuria Investment Co. Ltd. (Mercuria Investment) is an independent venture capital firm headquartered in Tokyo, Japan. The firm was founded in 2005 as a joint venture of Development Bank of Japan Inc. and Asuka Asset Management Co. Ltd.

Mercuria Investment Co. Ltd. (Mercuria Investment) is an independent venture capital firm headquartered in Tokyo, Japan. The firm was founded in 2005 as a joint venture of Development Bank of Japan Inc. and Asuka Asset Management Co. Ltd.

Mercuria Investment Co. Ltd. (Mercuria Investment) is an independent venture capital firm headquartered in Tokyo, Japan. The firm was founded in 2005 as a joint venture of Development Bank of Japan Inc. and Asuka Asset Management Co. Ltd.

Mercuria Investment Co., Ltd. provides investment advisory and management. Its activities include corporate investment, real estate, lease, and infrastructure. The company was founded on October 5, 2005 and is headquartered in Tokyo, Japan.

Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA.

Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA.

Mercuria Investment Co., Ltd. provides investment advisory and management. Its activities include corporate investment, real estate, lease, and infrastructure. The company was founded on October 5, 2005 and is headquartered in Tokyo, Japan.

Mercuria Investment Co., Ltd. provides investment advisory and management. Its activities include corporate investment, real estate, lease, and infrastructure. The company was founded on October 5, 2005 and is headquartered in Tokyo, Japan.

Admiral Capital Co Ltd (Admiral Capital) is a private equity subsidiary of SBI Holdings Inc founded by Reiko Kinosita in 2006. The firm is headquartered in Tokyo, Japan.

Mercuria Investment Co. Ltd. (Mercuria Investment) is an independent venture capital firm headquartered in Tokyo, Japan. The firm was founded in 2005 as a joint venture of Development Bank of Japan Inc. and Asuka Asset Management Co. Ltd.

Mercuria Investment Co. Ltd. (Mercuria Investment) is an independent venture capital firm headquartered in Tokyo, Japan. The firm was founded in 2005 as a joint venture of Development Bank of Japan Inc. and Asuka Asset Management Co. Ltd.

Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA.

Mercuria Investment Co. Ltd. (Mercuria Investment) is an independent venture capital firm headquartered in Tokyo, Japan. The firm was founded in 2005 as a joint venture of Development Bank of Japan Inc. and Asuka Asset Management Co. Ltd.

Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA.

Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA.

Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA.

Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA.

Spring Asset Management Ltd. (Hong Kong) engages in the management of assets of Spring Real Estate Investment Trust (REIT). The company was founded on January 29, 2013 and is headquartered in Hong Kong.

Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA.

Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA.

Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA.

Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA.

Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA.

Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA.

Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA.